Astera Labs (NASDAQ:ALAB) Shares Down 11.7% - Here's What Happened

Key Points

• Astera Labs shares fell 11.7% to about $256.57 in Friday trading, with volume substantially below the stock’s average session volume.
• Analyst sentiment remains mixed: Northland Securities and Citigroup downgraded the stock, while the broader analyst consensus is still “Moderate Buy” with a $340.79 target price.
• The company reported strong recent operating results, including $0.80 EPS versus $0.69 expected and 104.5% year-over-year revenue growth, although insiders have sold roughly $127.3 million of shares over the past 90 days.

Astera Labs, Inc. (NASDAQ:ALAB - Get Free Report)'s stock price was down 11.7% during trading on Friday. The company traded as low as $259.06 and last traded at $256.5710. 1,628,134 shares were traded during mid-day trading, a decline of 68% from the average session volume of 5,065,164 shares. The stock had previously closed at $290.43.

Wall Street Analyst Weigh In

ALAB has been the subject of a number of research reports. Northland Securities lowered shares of Astera Labs from an "outperform" rating to a "market perform" rating in a research note on Friday, October 9th. Susquehanna raised their price target on Astera Labs from $230.00 to $275.00 and gave the stock a "neutral" rating in a research note on Friday, July 31st. Roth Capital restated a "buy" rating and issued a $450.00 price target on shares of Astera Labs in a research note on Wednesday, August 5th. Citigroup lowered Astera Labs from a "buy" rating to a "hold" rating in a report on Friday, October 9th. Finally, Royal Bank Of Canada lifted their price objective on Astera Labs from $425.00 to $500.00 and gave the stock an "outperform" rating in a report on Wednesday, August 5th. Eleven equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $340.79.

Astera Labs Stock Down 13.8%

The company has a fifty day simple moving average of $308.75 and a 200-day simple moving average of $254.55. The firm has a market cap of $43.42 billion, a P/E ratio of 123.95 and a beta of 3.68.

Astera Labs (NASDAQ:ALAB - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.80 earnings per share for the quarter, beating analysts' consensus estimates of $0.69 by $0.11. The firm had revenue of $392.40 million for the quarter, compared to analysts' expectations of $360.85 million. Astera Labs had a return on equity of 19.24% and a net margin of 30.74%. The business's quarterly revenue was up 104.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.44 EPS. Astera Labs has set its Q3 2026 guidance at 1.160-1.210 EPS. As a group, research analysts forecast that Astera Labs, Inc. will post 2.71 EPS for the current year.

Insider Activity at Astera Labs

In other Astera Labs news, General Counsel Philip Mazzara sold 6,801 shares of the firm's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $340.50, for a total transaction of $2,315,740.50. Following the sale, the general counsel directly owned 96,542 shares of the company's stock, valued at $32,872,551. This trade represents a 6.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Jitendra Mohan sold 90,630 shares of the firm's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $340.35, for a total value of $30,845,920.50. Following the sale, the chief executive officer directly owned 1,266,665 shares in the company, valued at approximately $431,109,432.75. This represents a 6.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 408,558 shares of company stock worth $127,306,034 in the last 90 days. Company insiders own 10.40% of the company's stock.

Hedge Funds Weigh In On Astera Labs

A number of hedge funds have recently made changes to their positions in the business. BlackRock Inc. bought a new position in shares of Astera Labs during the 2nd quarter valued at approximately $6,609,581,000. ABS Investment Management LLC bought a new stake in shares of Astera Labs in the 2nd quarter worth about $1,980,382,000. Van ECK Associates Corp lifted its holdings in shares of Astera Labs by 20.0% in the 2nd quarter. Van ECK Associates Corp now owns 2,237,961 shares of the company's stock worth $1,080,980,000 after acquiring an additional 373,545 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of Astera Labs in the 2nd quarter worth about $1,061,791,000. Finally, Atreides Management LP purchased a new position in shares of Astera Labs during the 2nd quarter worth about $587,736,000. Institutional investors own 60.47% of the company's stock.

Astera Labs Company Profile

Astera Labs, Inc is a semiconductor and connectivity solutions company that develops hardware and software for data centers, cloud computing, and artificial intelligence infrastructure. Its products are designed to help move data between processors, memory, storage, and networking components while addressing bandwidth, latency, and system-management requirements.

The company's portfolio includes Aries PCI Express and Compute Express Link (CXL) Smart Retimers, Taurus Ethernet Smart Cable Modules, Scorpio Smart Fabric Switches, and Leo CXL Memory Connectivity Controllers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.